Literature DB >> 1561799

Cutaneous melanomas exhibiting unusual biologic behavior.

H M Shaw1, J K Rivers, S W McCarthy, W H McCarthy.   

Abstract

In rare instances, primary malignant melanoma thickness fails to predict the biologic course of the disease: lesions less than 0.8 mm thick may recur locally or metastasize, lesions greater than 5.5 mm thick may not prove to be fatal within the expected interval of time, and melanoma recurrences may develop greater than 10 years after first definitive melanoma treatment. The large Sydney Melanoma Unit data base of over 9,500 patients treated over a 41-year period provided a unique opportunity to study the characteristics and prognosis of these patients with unusual melanomas. In stage I patients with thin lesions, and no sign of disease elsewhere, presence of ulceration, high mitotic activity, and/or penetration into the reticular dermis predisposed these melanomas to recur and regression did not emerge as a risk factor for recurrence. This was in sharp contrast to the histology of the thin lesions in patients with concurrent regional lymph node metastases (stage II). Moderate to severe regression was present in all the latter lesions, ulceration and mitoses were absent, and none penetrated beyond the papillary dermis. No specific criteria were found that could identify those stage I or II patients with thick melanomas but at low risk for recurrence or those patients with localized disease (stage I) who required long-term follow-up beyond 10 years. These results indicate that guidelines for follow-up of melanoma patients after first definitive treatment may not be appropriate for a small proportion of patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1561799     DOI: 10.1007/bf02071521

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  31 in total

1.  Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases.

Authors:  H M Shaw; S W McCarthy; W H McCarthy; J F Thompson; G W Milton
Journal:  Histopathology       Date:  1989-09       Impact factor: 5.087

2.  Metastases of thin melanomas.

Authors:  H Trau; D S Rigel; M N Harris; A W Kopf; R J Friedman; S L Gumport; R S Bart; W R Grier
Journal:  Cancer       Date:  1983-02-01       Impact factor: 6.860

3.  Biologic behavior of thin malignant melanomas with regressive changes.

Authors:  R R Paladugu; R H Yonemoto
Journal:  Arch Surg       Date:  1983-01

4.  Can late recurrence of melanoma be predicted at the time of primary treatment.

Authors:  A K Khanna; P Laidler; L E Hughes
Journal:  Eur J Surg Oncol       Date:  1986-03       Impact factor: 4.424

5.  Lethal "thin" malignant melanoma. Identifying patients at risk.

Authors:  C L Slingluff; R T Vollmer; D S Reintgen; H F Seigler
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

6.  The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

Authors:  M A Gromet; W L Epstein; M S Blois
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

7.  Is malignant melanoma arising in a Hutchinson's melanotic freckle a separate disease entity?

Authors:  V J McGovern; H M Shaw; G W Milton; G A Farago
Journal:  Histopathology       Date:  1980-05       Impact factor: 5.087

8.  Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance.

Authors:  P H Cooper; H J Wanebo; R W Hagar
Journal:  Arch Dermatol       Date:  1985-09

9.  Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases.

Authors:  K Søndergaard; K Hou-Jensen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

10.  Late recurrence of stage I malignant melanoma.

Authors:  M Gutman; J M Klausner; M Inbar; R R Rozin
Journal:  J Surg Oncol       Date:  1989-10       Impact factor: 3.454

View more
  1 in total

1.  Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors.

Authors:  Sabina Zurac; Monica Neagu; Carolina Constantin; Mirela Cioplea; Roxana Nedelcu; Alexandra Bastian; Cristiana Popp; Luciana Nichita; Razvan Andrei; Tiberiu Tebeica; Cristiana Tanase; Virginia Chitu; Constantin Caruntu; Mihaela Ghita; Catalin Popescu; Daniel Boda; Bogdan Mastalier; Nicoleta Maru; Claudiu Daha; Bogdan Andreescu; Ioan Marinescu; Adrian Rebosapca; Florica Staniceanu; Gabriela Negroiu; Daniela A Ion; Dragana Nikitovic; George N Tzanakakis; Demetrios A Spandidos; Aristidis M Tsatsakis
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.